|
|
|
| Effect of L-Carnitine Combined with Astragalus Injection on Serum Myocardical Enzyme Markers in the Treatment of Acute Viral Myocarditis |
| WANG Xiao-xia, LIU Yue-ying, XU Wen-gang |
| Qingdao Municipal Hospital,Shandong province,Qingdao 266000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of L-carnitine combined with astragalus injection in the treatment of acute viral myocarditis (AVM) and explore its effect on serum myocardial enzyme markers. 【Methods】The clinical data of 104 patients with acute viral myocarditis received admitted our hospital were retrospectively studied. According to the different methods of administration, they were divided into the observation group (L-carnitine combined with Astragalus injection) and the control group (L-carnitine treatment only). There were 52 cases in each group. The therapeutic effects of the two groups were compared. Levels of serum myocardial enzyme markers and incidence of adverse reactions before and after treatment were compared as well. 【Results】After 2 weeks of treatment, the total effective rate of the observation group was 80.7% (42/52), which was higher than that of the control group 59.6% (31/52), and the difference was statistically significant (P<0.05). The levels of serum CK, CK-MB and CTnT in the two groups after treatment were lower than those before treatment; the CK, CK-MB and CTnT levels of the observation group were lower than those of the control group. The difference was statistically significant (P<0.05). There were no significant differences in the incidence of adverse reactions such as headache, allergic reaction, liver and kidney function damage, and dyspnea in the two groups (P>0.05).【Conclusion】L-carnitine combined with astragalus injection is effective in the treatment of acute viral myocarditis. It can effectively improve cardiac function, decrease levels of serum myocardial enzyme markers but not increase drug adverse reactions, which is worthy of clinical application.
|
|
Received: 17 December 2018
|
|
|
|
|
|
[1] 王青.曲美他嗪联合黄芪注射液治疗急性病毒性心肌炎的疗效及安全性[J].中国老年学杂志 ,2012,9(2):1820-1821.
[2] 朱伟雄,肖勇,严丽霞.1,6二磷酸果糖治疗小儿病毒性心肌炎疗效及对心电图和心肌酶谱的影响[J].实用医学杂志,2012,28(16):123-125.
[3] 徐慧,牛玲,左卡尼汀联合生脉注射液治疗小儿病毒性心肌炎疗效及对血清心肌肌钙蛋白I与肌酸激酶同工酶水平的影响[J].河北医学,2017,12(6):2076-2079.
[4] 杨禄辉,病毒性心肌炎的发病机制、诊断和治疗浅析[J].世界临床医学,2017,12(9):102-104.
[5] 王松云,赵劲波,江洪.参麦注射液联合黄芪注射液治疗成人病毒性心肌炎的 Meta分析[J].中国循证心血管医学杂志,2013,5(3):237-240.
[6] 宋金森.黄芪注射液与左旋卡尼汀联合治疗急性病毒性心肌炎临床疗效评价[J].医药论坛杂志,2011,32(20):163-164.
[7] 罗学斌,马静. 黄芪注射液与左旋卡尼汀注射液联合曲美他嗪治疗急性病毒性心肌炎的疗效观察[J].云南医药,2011,32(1):107-108. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(1): 160-162. |
|
|
|
|
2019, Vol. 36 
